| Literature DB >> 27872790 |
Shengchuan Dai1, Manoucher Manoucheri2, Junhong Gui2, Xiang Zhu3, Divyanshu Malhotra2, Shenjing Li4, Jason D'souza2, Fnu Virkram2, Aditya Chada2, Haibing Jiang2.
Abstract
Background. Heart failure (HF) is one of the most common diagnoses associated with hospital readmission. We designed this prospective study to evaluate whether Kansas City Cardiomyopathy Questionnaire (KCCQ) score is associated with 30-day readmission in patients hospitalized with decompensated HF. Methods and Results. We enrolled 240 patients who met the study criteria. Forty-eight (20%) patients were readmitted for decompensated HF within thirty days of hospital discharge, and 192 (80%) patients were not readmitted. Compared to readmitted patients, nonreadmitted patients had a higher average KCCQ score (40.8 versus 32.6, P = 0.019) before discharge. Multivariate analyses showed that a high KCCQ score was associated with low HF readmission rate (adjusted OR = 0.566, P = 0.022). The c-statistic for the base model (age + gender) was 0.617. The combination of home medication and lab tests on the base model resulted in an integrated discrimination improvement (IDI) increase of 3.9%. On that basis, the KCQQ further increased IDI of 2.7%. Conclusions. The KCCQ score determined before hospital discharge was significantly associated with 30-day readmission rate in patients with HF, which may provide a clinically useful measure and could significantly improve readmission prediction reliability when combined with other clinical components.Entities:
Year: 2016 PMID: 27872790 PMCID: PMC5107227 DOI: 10.1155/2016/4571201
Source DB: PubMed Journal: Cardiol Res Pract ISSN: 2090-0597 Impact factor: 1.866
Summary of demographic characteristics and medical history between HF readmission and nonreadmission within 30 days after discharge.
| Demographic characteristics | Readmission within 30 days after discharge | ||
|---|---|---|---|
| No ( | Yes ( |
| |
| Age, yrs, mean (SD) | 63.0 (13.6) | 59.9 (14.5) | 0.163 |
| LOS, days, mean (SD) | 11.2 (11.6) | 9.7 (7.6) | 0.420 |
|
| 0.743 | ||
| White | 115 (59.9) | 27 (56.3) | |
| Other | 77 (40.1) | 21 (43.8) | |
|
| 0.020 | ||
| Female | 60 (31.3) | 7 (14.6) | |
| Male | 132 (68.8) | 41 (85.4) | |
|
| |||
| CAD | 137 (71.4) | 28 (58.3) | 0.085 |
| MI | 75 (39.1) | 20 (41.7) | 0.744 |
| DM | 103 (53.7) | 26 (54.2) | 1.000 |
| Hypertension | 156 (81.3) | 38 (79.2) | 0.838 |
| COPD | 44 (22.9) | 10 (20.8) | 0.848 |
| ICD | 100 (52.1) | 22 (45.8) | 0.519 |
| LVAD | 8 (4.2) | 2 (4.2) | 1.000 |
| History of prior stroke | 19 (9.9) | 1 (2.1) | 0.139 |
| Obesity | 52 (27.1) | 13 (27.1) | 1.000 |
| At least one comorbidity | 186 (96.9) | 46 (95.8) | 0.662 |
Note. Numbers in the parenthesis are percentage except indicated.
Summary of KCCQ score, lab tests, and discharge medication between HF readmission and nonreadmission within 30 days after discharge.
| Demographic characteristics | Readmission within 30 days after discharge | ||
|---|---|---|---|
| No ( | Yes ( |
| |
| KCCQ score, mean (SD) | 40.8 (22.2) | 32.6 (18.5) | 0.019 |
|
| |||
| Sodium, mean (SD) | 137.6 (4.7) | 137.5 (5.6) | 0.915 |
| HGB, mean (SD) | 12.1 (2.1) | 11.9 (2.1) | 0.622 |
| Ejection fraction | 24.7 (7.4) | 21.8 (8.8) | 0.021 |
|
| |||
| Beta blocker | 172 (89.6) | 43 (89.6) | 1.000 |
| ACE/ARB | 110 (57.3) | 25 (52.1) | 0.520 |
| Diuretic | 168 (87.5) | 40 (83.3) | 0.478 |
| Lipid-lowering | 126 (65.6) | 29 (60.4) | 0.504 |
| Aldosterone antagonist | 98 (51.0) | 23 (47.9) | 0.748 |
| Digoxin | 60 (31.3) | 15 (31.3) | 1.000 |
| Hydralazine | 30 (15.6) | 5 (10.4) | 0.494 |
| Nitrates | 39 (20.3) | 6 (12.5) | 0.301 |
| Inotrope | 46 (24.0) | 13 (27.1) | 0.708 |
Note. Numbers in the parenthesis are percentage except indicated.
Summary of multivariate analysis investigating the effects of demographic characteristics, medical history, discharge medication, lab test, and overall KCCQ score on readmission rate within 30 days after discharge (n = 240).
| Factor | Adjusted OR | SE | 95% CI |
|
|---|---|---|---|---|
| Age | 0.990 | 0.145 | 0.742–1.320 | 0.946 |
| White | 0.821 | 0.348 | 0.358–1.884 | 0.642 |
| Male | 5.589 | 2.962 | 1.979–15.79 | 0.001 |
| CAD | 0.231 | 0.135 | 0.074–0.724 | 0.012 |
| MI | 2.849 | 1.514 | 1.005–8.074 | 0.049 |
| DM | 0.877 | 0.369 | 0.384–2.001 | 0.754 |
| Hypertension | 0.815 | 0.405 | 0.308–2.157 | 0.681 |
| COPD | 1.084 | 0.514 | 0.429–2.744 | 0.864 |
| ICD | 0.648 | 0.271 | 0.286–1.471 | 0.299 |
| LVAD | 0.710 | 0.650 | 0.118–4.275 | 0.709 |
| History of prior stroke | 0.150 | 0.171 | 0.016–1.402 | 0.096 |
| Obesity | 1.377 | 0.658 | 0.540–3.511 | 0.503 |
| Beta blocker | 1.096 | 0.713 | 0.306–3.920 | 0.888 |
| ACE/ARB | 0.734 | 0.299 | 0.331–1.629 | 0.447 |
| Diuretic | 0.438 | 0.257 | 0.138–1.384 | 0.159 |
| Lipid-lowering | 1.186 | 0.511 | 0.509–2.761 | 0.693 |
| Aldosterone antagonist | 0.873 | 0.360 | 0.389–1.957 | 0.741 |
| Digoxin | 1.137 | 0.47 | 0.506–2.554 | 0.756 |
| Hydralazine | 0.639 | 0.402 | 0.186–2.193 | 0.476 |
| Nitrates | 0.443 | 0.271 | 0.134–1.467 | 0.182 |
| Inotrope | 0.799 | 0.378 | 0.316–2.022 | 0.636 |
| Sodium | 1.791 | 0.815 | 0.734–4.368 | 0.200 |
| Hgb | 0.810 | 0.087 | 0.655–1.000 | 0.050 |
| Ejection fraction | 1.903 | 0.532 | 1.100–3.292 | 0.021 |
| KCCQ | 0.566 | 0.141 | 0.347–0.922 | 0.022 |
Figure 1Adjusted odds ratios of readmission within 30 days after discharge derived from multivariate logistic regression analysis.
Figure 2Comparison of ROC area among different models. Model 1: logit (read30) = age + gender; model 2: logit (read30) = age + gender + beta_blocker + ace/arb; model 3: logit (read30) = age + gender + beta_blocker + ace/arb + sodium + hgb; model 4: logit (read30) = age + gender + beta_blocker + ace/arb + sodium + hgb + ef; and model 5: logit (read30) = age + gender + beta_blocker + ace/arb + sodium + hgb + ef + KCCQ. read30: readmission in 30 days.
Prognostic value of readmission within 30 days after discharge of different models comparing to model 1 with only demographic predictors.
| Model |
| IDI increase (%) |
|
|---|---|---|---|
| Model 1: age + gender | 0.617 | — | — |
| Model 2: age + gender + beta_blocker + ace/arb | 0.647 | 0.9 | 0.123 |
| Model 3: age + gender + beta_blocker + ace/arb + sodium + hgb | 0.656 | 1.3 | 0.081 |
| Model 4: age + gender + beta_blocker + ace/arb + sodium + hgb + ef | 0.670 | 3.9 | 0.005 |
| Model 5: age + gender + beta_blocker + ace/arb + sodium + hgb + ef + KCCQ | 0.710 | 6.6 | <0.001 |